RT Journal Article
SR Electronic
T1 Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.25.23296068
DO 10.1101/2023.09.25.23296068
A1 Caini, Saverio
A1 Meijer, Adam
A1 Nunes, Marta C.
A1 Henaff, Laetitia
A1 Zounon, Malaika
A1 Boudewijns, Bronke
A1 Riccio, Marco Del
A1 Paget, John
YR 2023
UL http://medrxiv.org/content/early/2023/09/25/2023.09.25.23296068.abstract
AB Introduction Early after the start of the COVID-19 pandemic, a major drop in the number of influenza B/Yamagata detections was observed globally. Given the potential public health implications, particularly with regards to influenza vaccination, we conducted a systematic review of influenza B/Yamagata virus circulation data from multiple complementary sources of information.Methods We searched articles published until 20th March 2023 in PubMed and EMBASE; examined epidemiological and virological influenza data for 2020-2023 contained in the publicly available WHO-FluNet and GISAID (Global Initiative on Sharing All Influenza Data) global databases, or collected by the multi-national Global Influenza Hospital Surveillance Network (GIHSN) study; and looked for influenza data in the webpages of respiratory viruses surveillance systems from countries worldwide.Results Highly consistent findings were found across all sources of information, with a progressive decline of influenza B/Yamagata detections from 2020 onwards across all world regions, both in absolute terms (total number of cases), the positivity rate, and as a fraction of influenza B detections. Isolated influenza B/Yamagata cases continue to be sporadically reported, and these are typically vaccine-derived, mistaken data entries or under investigation.Discussion While it is still too early to conclude that B/Yamagata is (or will soon become) extinct, the current epidemiological and virological data call for a rapid response in terms of influenza prevention practices, particularly regarding the formulation of influenza vaccines. The current epidemiological situation is unprecedented in recent decades, underlying the importance of continuously and carefully monitoring the circulation of influenza viruses (as well as SARS-CoV-2 and the other respiratory viruses) in the coming years.Competing Interest StatementSaverio Caini, Adam Meijer, Laetitia Henaff and Malaika Zounon received no specific finding for this work. John Paget, Marco Del Riccio and Bronke Boudewijns were funded via a research grant from Sanofi to NIVEL (FluCov project). Marta Nunes was funded via a research grant from Sanofi to CERP.Funding StatementSaverio Caini, Adam Meijer, Laetitia Henaff and Malaika Zounon received no specific finding for this work. John Paget, Marco Del Riccio and Bronke Boudewijns were funded via a research grant from Sanofi to NIVEL (FluCov project). Marta Nunes was funded via a research grant from Sanofi to CERP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis is a review of data in the public domain.